Alnylam Pharma (ALNY) Misses Q2 EPS by 10c
Tweet
Share
E-mailGet Alerts ALNY Hot Sheet
Price: $298.76 -4.49%
EPS Growth %: +403.1%
Financial Fact:
Net loss: -90.13M
Today's EPS Names:
CCEL, FEIM, PLG, More
EPS Growth %: +403.1%
Financial Fact:
Net loss: -90.13M
Today's EPS Names:
CCEL, FEIM, PLG, More
Join SI Premium – FREE
Alnylam Pharma (NASDAQ: ALNY) reported Q2 EPS of ($0.85), $0.10 worse than the analyst estimate of ($0.75). Revenue for the quarter came in at $8.69 million versus the consensus estimate of $12.64 million.
For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Baird on Nurix (NRIX) Earnings Amid 7% Drop: '2Q Print Solid as Breadth of Development Expands'
- What Delta’s report tells investors in American and United
- Increasing unusual call volume: ACI LEVI IHI FE KHC BBIO IONS OCUL XME DOMO ALNY
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
